* Lehman Brothers has completed one of the most successful French IPOs this year with the sale of stock in bio-tech group Transgene. The offering, which was around 15 times oversubscribed, results in a dual listing for the company on the Nouveau Marché and Nasdaq. Lehman and joint lead manager Credit Suisse First Boston were able to close the deal in the face of heavy oversubscription -- pricing the stock at $14.50, the top of the indicated price range. Some 1.314m GDRs were sold to investors with each receipt representing three shares. The joint leads were joined by Crédit Lyonnais and Lazard Capital Markets as co-managers.
March 27, 1998